• Perseus

  Participated · Series B · Jun 2026

  Perseus develops core foundational software for the automotive industry, focusing on hypervisor technology that integrates and controls complex in-vehicle electronic systems. The company's technology targets improved safety and resource efficiency in Software-Defined Vehicles and has achieved ASIL D safety certification. Founded by CEO Sang-bum Suh, Perseus is based in South Korea. The company plans to expand its product applications beyond automotive into industrial sectors including defense, smart factories, humanoid robots, and satellites. Financially, Perseus announced this Series B raise of 16 billion won which increases its cumulative funding to over 30 billion won. The company intends to use the new capital to advance its hypervisor technology and accelerate global market expansion.

• Logpresso

  Participated · Series B · Dec 2025

  Logpresso builds a unified security platform that combines open, extensible XDR with AI agent–based security operations to help organizations detect and respond to threats. Its technology features lightweight large language model (sLLM) functionality and can run in closed networks, allowing analysts to conduct natural-language investigations such as asking the system to find and assess potential data exfiltration events. The company is rolling out an alliance program with 14 domestic security vendors and plans to formally launch the XDR product in the first half of next year. Having proven its software-as-a-service capability with multiple Korean customers, Logpresso intends to enter Japan first and then expand into North America and Western Europe. Management is targeting an initial public offering in 2028, with Daishin Securities serving as lead underwriter. Including the new investment, Logpresso has raised a cumulative ₩230 billion (approximately US$170 million) since its 2019 seed round and 2023 Series A. No revenue or user metrics were disclosed in the article.

• Colosseum

  Participated · Series B · Jun 2025

  Colosseum offers an AI-powered integrated logistics platform called COLO AI that automates the entire logistics process from order intake and inventory management to last-mile delivery. COLO AI unifies key supply chain functions including order management, warehouse management, and transportation management systems. The company supports e-commerce, B2B, and cross-border fulfillment with a focus on K-beauty and other Korean products. Founded in 2019 and based in Seoul, Colosseum operates 53 logistics centers worldwide. The company plans to use recent funding to support global expansion into the U.S., Japan, and Southeast Asia and to expand its logistics infrastructure. It will also use proceeds to further develop COLO AI. Financially, Colosseum completed a KRW 27 billion Series B in June 2025. Colosseum Corporation operates a global logistics-center network (41 sites totaling about 260,000 m²) and offers e‑commerce and cross‑border fulfillment, freight forwarding, and corporate/food logistics. The company sells an internally developed integrated AI logistics solution called "COLO" and employs a logistics-expert group called FD (Fulfillment Director) to manage complex, data-driven operations. Colosseum emphasizes digitalizing collaboration among warehouses, carriers, and forwarders to deliver real-time visibility and seamless logistics experiences. It markets capabilities in handling diverse product categories, packaging and delivery methods, and export/import logistics while optimizing dispatch and fulfillment readiness. Colosseum recently adopted a multiple‑voting share structure to secure stable management for global expansion, has established a U.S. subsidiary, and is accelerating expansion into the U.S., Southeast Asia, and Japan. The company and its investor partner plan to pursue collaborative projects to apply Colosseum's systems to Hyosung subsidiaries in Vietnam and other countries. Colosseum operates an integrated AI logistics solution called COLO and a global logistics expert group (FD) to connect a network of 38 logistics centers, mid‑ and last‑mile delivery, and automation equipment. The company provides e‑commerce fulfillment, retail/B2B, urban MFCs, cross‑border logistics and end‑to‑end consulting services. Since its 2019 founding, Colosseum has achieved more than threefold annual growth in both revenue and shipment volume. It recently launched a global version of COLO and completed a second round of product enhancements to support international operations and improve OMS/WMS/TMS integration, intelligence and UX. Colosseum plans to expand its logistics‑center network to more than 100 sites within three years and to broaden service lines into foodservice/franchise logistics and freight transport. The company is accelerating global expansion into markets including North America and Southeast Asia and is establishing local subsidiaries to scale cross‑border and local logistics services. Colosseum is also testing commercialization of mobile and vision‑based automation robots and equipment targeted for the first half of next year.

• Nexeon

  Participated · Equity · Aug 2022

  Nexeon has developed silicon-carbon and silicon-based anode technologies aimed at increasing energy density and improving performance relative to conventional battery materials. The company targets applications such as electric vehicles and other sectors seeking higher-performance lithium-ion batteries. Nexeon is moving into a phase focused on scaling production and accelerating commercialisation of its technology. Management characterized the Honda investment as validation of the company's technology and commercial traction. The partnership with Honda is expected to strengthen development and deployment of Nexeon's materials as demand for higher-performance batteries grows. The articles do not provide financial metrics, year founded, or location.

• Standigm

  Led · Equity · Mar 2021

  Standigm develops workflow AI technology that spans novel target identification, lead generation, and drug repurposing through proprietary platforms such as Standigm ASK™, Standigm BEST™, Standigm Insight™ and the automated DarkMolFactory™. The company says it can generate first-in-class lead compounds within seven months and currently runs 22 in-house or collaborative drug pipelines. The recent $10 million investment will be used for clinical research of AI-driven drug compounds to strengthen Standigm’s competitiveness in the global market. Standigm has completed a series of investments from SK Chemicals and Pavilion Capital following a Pre-IPO funding round in March. NH Investment & Securities has been in charge of Standigm’s IPO process since March last year, indicating an ongoing push toward public markets. Founded in 2015 and headquartered in Seoul, Standigm is pursuing full-stack, AI-driven industrialization of drug discovery by automating molecular design and expanding automation across the discovery process. Standigm applies proprietary AI platforms to industrialize drug discovery, covering target identification, lead generation, repurposing, and automated molecular design. Its platforms include Standigm ASK™ for target discovery, Standigm BEST™ for lead selection, Standigm Insight™ for repurposing, and DarkMolFactory™ for automated molecular design. The company reports more than 20 preclinical pipelines and collaborations with over ten pharmaceutical or academic partners, including SK chemicals, Hanmi Pharmaceuticals, HK inno.N, and Samjin Pharmaceutical. Standigm and SK holdings C&C opened the iCLUE&ASK™ target-identification platform to the public in September. Management says proceeds from the recent financing will bolster B2B sales and support FDA investigational new drug (IND) filings and global collaborations. Standigm holds two patents for its AI technology granted in 2021 and has repurposed an FDA-approved drug for rheumatoid arthritis with a partner and filed for a patent.

No current team members are available.